Fresenius Medical Care is reorganizing its global and leadership roles, the dialysis provider announced Wednesday.
The for-profit company is consolidating its international service areas and creating a global care delivery segment that will launch in 2023. In the meantime, Fresenius Medical Care is reshuffling executives as it prepares to implement the new corporate structure.
"2022 will be a significant year of transition as we move toward our new operating model as a leaner, and at the same time stronger, basis for executing our growth strategy," Fresenius Medical Care CEO Rice Powell said in a news release.
The overarching goal of the restructuring is to bring its operations in different countries together under one umbrella and replace the regional management system currently in place.
William Valle, the current CEO of Fresenius Medical Care North America, will lead the company's new international care delivery segment. Dr. Katarzyna Mazur-Hofsäss will shift from her role as CEO of European, Middle Eastern and African operations to preside over a new care enablement segment encompassing its medical technology offerings.
Helen Giza will take on the position of chief transformation officer in addition to her responsibilities as chief financial officer during the conversion to the new operating model.
Harry de Wit, current CEO of the company's Asia-Pacific operations, Kent Wanzek, CEO of global manufacturing, quality and supply, and Dr. Olaf Schermeier, CEO of global research and development, will all transition from the company's management board to its executive committee.
Powell will remain CEO and Dr. Franklin Maddux will continue to serve as global chief medical officer.
Worldwide, Fresenius Medical Care provides treatment to around 345,000 patients with renal diseases at its 4,151 dialysis clinics. In total, the company employs 300,000 people in 100 countries and brings in billions in revenue annually.
